RxDoctor Payments Data

Prashanth Muthukrishnan, MD

Pulmonary Disease · Douglasville, GANPI 1841549227

Payments from drug & device makers

$5,791in general payments, 2019–2025

Across 34 payments — averaging $170.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Veran Medical Technologies, Inc.$767
  • AstraZeneca$378
  • E.r. Squibb & Sons, L.L.C.$120
  • Boehringer Ingelheim$80
  • Regeneron Healthcare Solutions, Inc.$68
  • plus $257 from 7 others

What the payments were for

  • Travel & lodging$1,32123%
  • Food & beverage$1,47025%
  • Education$3,00052%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,791 in reported general payments places this provider in the 50th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$70,834
Medicare patients
278
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fasenra PenBenralizumab77$430,619
Trelegy ElliptaFluticasone/Umeclidin/Vilanter167$146,437
NucalaMepolizumab17$63,037
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$32,767
Stiolto RespimatTiotropium Br/Olodaterol Hcl57$26,828
Breo ElliptaFluticasone/Vilanterol40$24,079
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$22,090
SymbicortBudesonide/Formoterol Fumarate38$18,427
Spiriva RespimatTiotropium Bromide25$17,359
Spiriva HandihalerTiotropium Bromide27$14,583
Fluticasone-SalmeterolFluticasone Propion/Salmeterol80$12,820
Incruse ElliptaUmeclidinium Bromide24$8,173
Roflumilast51$5,557
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$5,400
Wixela InhubFluticasone Propion/Salmeterol19$2,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$62$263,817294 claims
AstraZenecaBreztri Aerosphere, Symbicort$378$51,19484 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$80$44,18782 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Douglasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →